“Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy

[1]  T. Phillips,et al.  Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin , 1992, Molecular and Cellular Biochemistry.

[2]  R. Dinsmore,et al.  The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention , 1993, Cardiovascular Drugs and Therapy.

[3]  M. Aviram,et al.  Angiotensin II Enhances Lipid Peroxidation of Low-Density Lipoprotein , 1993 .

[4]  I. Simpson,et al.  Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. , 1993, The American journal of cardiology.

[5]  A. Husain.  The chymase-angiotensin system in humans. , 1993, Journal of hypertension.

[6]  M. Kronenberg,et al.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. , 1993, Circulation.

[7]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[8]  S. Yusuf,et al.  Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. , 1993, Journal of the American College of Cardiology.

[9]  J. Cohn,et al.  Mechanism of Death in Heart Failure The Vasodilator‐Heart Failure Trials , 1993, Circulation.

[10]  A. Salvetti,et al.  Vasodilation to acetylcholine in primary and secondary forms of human hypertension. , 1993, Hypertension.

[11]  T. Baussant,et al.  Angiotensin‐Converting Enzyme Inhibition Does Not Suppress Plasma Angiotensin II Increase During Exercise in Humans , 1993, Journal of cardiovascular pharmacology.

[12]  A. Donker,et al.  Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. , 1993, The American journal of cardiology.

[13]  K. Weber,et al.  Aldosterone and antialdosterone therapy in congestive heart failure. , 1993, The American journal of cardiology.

[14]  A. Branzi,et al.  Evidence of a Partial Escape of Renin‐Angiotensin‐Aldosterone Blockade in Patients with Acute Myocardial Infarction Treated with Ace Inhibitors , 1993, Journal of clinical pharmacology.

[15]  M. Konstam,et al.  Progression of Left-ventricular Dysfunction During Enalapril Therapy - Relationship With Neurohormonal Reactivation , 1993 .

[16]  F. Suzuki,et al.  [Renin-angiotensin system]. , 1992, Nihon rinsho. Japanese journal of clinical medicine.

[17]  B. Pitt,et al.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.

[18]  K. Theisen,et al.  Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. , 1992, The American journal of physiology.

[19]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[20]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[21]  M. Eisenberg,et al.  Magnesium deficiency and sudden death. , 1992, American heart journal.

[22]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[23]  M. Raizada,et al.  Angiotensin II stimulation of plasminogen activator inhibitor-1 gene expression in astroglial cells from the brain. , 1992, Endocrinology.

[24]  L. Lind,et al.  Metabolic cardiovascular risk factors and the renin-aldosterone system in essential hypertension. , 1992, Journal of human hypertension.

[25]  T. Lüscher,et al.  Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. , 1992, Hypertension.

[26]  M. A. Plant.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality , 1991 .

[27]  J. Kaufman,et al.  Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. , 1991, The American journal of cardiology.

[28]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[29]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[30]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[31]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[32]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[33]  R D Fish,et al.  Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. , 1990, Circulation.

[34]  M. Weir,et al.  The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .

[35]  B. Healy,et al.  Coronary reserve is depressed in postmyocardial infarction reactive cardiac hypertrophy. , 1990, Circulation.

[36]  M. Murnane,et al.  Magnesium content of serum, circulating mononuclear cells, skeletal muscle, and myocardium in congestive heart failure. , 1989, Circulation.

[37]  Y. Hirata,et al.  Endothelin is a potent mitogen for rat vascular smooth muscle cells. , 1989, Atherosclerosis.

[38]  V. Dzau,et al.  Angiotensin II Induces c‐fos Expression in Smooth Muscle Via Transcriptional Control , 1989, Hypertension.

[39]  S. Gottlieb.  Importance of magnesium in congestive heart failure. , 1989, The American journal of cardiology.

[40]  K. Okumura,et al.  Effect of magnesium on anginal attack induced by hyperventilation in patients with variant angina. , 1989, Circulation.

[41]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[42]  J. Madwed,et al.  Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs. , 1988, The American journal of physiology.

[43]  K. Kjeldsen,et al.  Reduced concentrations of potassium, magnesium, and sodium-potassium pumps in human skeletal muscle during treatment with diuretics , 1988, British medical journal.

[44]  M. Wilén,et al.  Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. , 1988, JAMA.

[45]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[46]  M. Marcus,et al.  Alterations of Vascular Reactivity in Atherosclerosis , 1987, Circulation research.

[47]  T. Strasser,et al.  Effect of aldosterone on sodium and potassium concentrations in human mononuclear leukocytes. , 1987, The American journal of physiology.

[48]  Vascular Angiotensin Pathways: A New Therapeutic Target , 1987, Journal of cardiovascular pharmacology.

[49]  P. Wester,et al.  Intracellular electrolytes in cardiac failure. , 2009, Acta medica Scandinavica. Supplementum.

[50]  J. Muller.  Spironolactone in the management of congestive cardiac failure: a review. , 1986, Clinical therapeutics.

[51]  M. Ryan,et al.  Magnesium depletion as a cause of refractory potassium repletion. , 1985, Archives of internal medicine.

[52]  J. Staessen,et al.  Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.

[53]  B. Altura,et al.  Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. , 1980, Science.

[54]  W F Ganong,et al.  The renin-angiotensin system. , 1978, Annual review of physiology.

[55]  C. Carpenter,et al.  The role of the renin-angiotensin system in the control of aldosterone secretion. , 1962, The Journal of clinical investigation.